参考文献/References:
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68: 7-30.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424.
[3] Yashiro H, Nakatsuka S, Inoue M, et al. Factors affecting local progression after percutaneous cryoablation of lung tumors[J]. J Vasc Interv Radiol, 2013, 24: 813-821.
[4] Mcdevitt JL, Mouli SK, Nemcek AA, et al. Percutaneous cryoablation for the treatment of primary and metastatic lung tumors: identification of risk factors for recurrence and major complications[J]. J Vasc Interv Radiol, 2016, 27: 1371-1379.
[5] 赵真真， 王忠敏， 茅爱武. 非小细胞肺癌的介入治疗现状[J]. 介入放射学杂志， 2014， 23：272-276.
[6] Hinshaw JL, Littrup PJ, Durick N, et al. Optimizing the protocol for pulmonary cryoablation: a comparison of a dual-and triple-freeze protocol[J]. Cardiovasc Intervent Radiol, 2010, 33: 1180-1185.
[7] Niu L, Li J, Chen J, et al. Comparison of dual-and triple-freeze protocols for pulmonary cryoablation in a Tibet pig model[J]. Cryobiology, 2012, 64: 245-249.
[8] 曾健滢， 施娟娟， 牛?涛. 3次循环冷冻治疗进展期非小细胞肺癌近期疗效[J]. 介入放射学杂志， 2018， 27：1085-1089.
[9] Korpan N. History of Cryosurgery[M]. Springer Vienna : Atlas of Cryosurgery, 2001.
[10] Korpan NN. Living matter: the “lunar eclipse” phenomena[J]. Lik Sprava, 2010: 135-144.
[11] Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery[J]. Cryobiology, 1998, 37: 171-186.
[12] Brown NJ, Bayjoo P, Reed MW. Effect of cryosurgery on liver blood flow[J]. Br J Cancer, 1993, 68: 10-12.
[13] Zhang X, Tian J, Zhao L, et al. CT-guided conformal cryoablation for peripheral NSCLC: initial experience[J]. Eur J Radiol, 2012, 81: 3354-3362.
[14] 魏颖恬， 肖越勇. 影像学引导肺癌冷冻消融治疗专家共识2018
版[J]. 中国介入影像与治疗学， 2018， 15：259-263.
[15] El-Sherif A, Gooding WE, Santos R, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis[J]. Ann Thorac Surg, 2006, 82: 408-415.
[16] Landreneau RJ, Sugarbaker DJ, Mack MJ, et al. Wedge resection versus lobectomy for stage I （T1 N0 M0） non-small-cell lung cancer[J]. J Thorac Cardiovasc Surg, 1997, 113: 691-698; discussion 698-700.
[17] Moore W, Talati R, Bhattacharji P, et al. Five-year survival after cryoablation of stage i non-small cell lung cancer in medically inoperable patients[J]. J Vasc Interv Radiol, 2015, 26: 312-319.
[18] Yamauchi Y, Izumi Y, Hashimoto K, et al. Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer[J]. PLoS One, 2012, 7: e33223.
[19] Zemlyak A, Moore WH, Bilfinger TV. Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer[J]. J Am Coll Surg, 2010, 211: 68-72.
[20] de Baere T, Tselikas L, Woodrum D, et al. Evaluating cryoablation of metastatic lung tumors in patients: safety and efficacy. The ECLIPSE trial-interim analysis at 1 year[J]. J Thorac Oncol, 2015, 10: 1468-1474.
[21] Niu L, Chen J, Yao F, et al. Percutaneous cryoablation for stageⅣ lung cancer: a retrospective analysis[J]. Cryobiology, 2013, 67: 151-155.
[22] Gao W, Guo Z, Shu S, et al. The application effect of percutaneous cryoablation for the stage ⅢB/Ⅳ advanced non-small-cell lung cancer after the failure of chemoradiotherapy[J]. Asian J Surg, 2018, 41: 530-536.
[23] 杜显峰， 韩宝石， 李天志. 氩氦刀治疗中晚期非小细胞肺癌的Meta分析[J]. 军医进修学院学报， 2010， 31：714-717.
[24] Nakajima R, Yokose T, Kakinuma R, et al. Localized pure ground-glass opacity on high-resolution CT: histologic characteristics[J]. J Comput Assist Tomogr, 2002, 26: 323-329.
[25] Park JH, Lee KS, Kim JH, et al. Malignant pure pulmonary ground-glass opacity nodules: prognostic implications[J]. Korean J Radiol, 2009, 10: 12-20.
[26] Kim KY, Jin GY, Han YM, et al. Cryoablation of a small pulmonary nodule with pure ground-glass opacity: a case report[J]. Korean J Radiol, 2015, 16: 657-661.
[27] Liu S, Zhu X, Qin Z, et al. Computed tomography-guided percutaneous cryoablation for lung ground-glass opacity: a pilot study[J]. J Cancer Res Ther, 2019, 15: 370-374.
[28] Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25, 676， 887 patients from 279 population-based registries in 67 countries （CONCORD-2）[J]. Lancet, 2015, 385: 977-1010.
[29] Kelly RJ, Sharon E, Hassan R. Chemotherapy and targeted therapies for unresectable malignant mesothelioma[J]. Lung Cancer, 2011, 73: 256-263.
[30] Clarke DM, Baust JM, Van Buskirk RG, et al. Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer[J]. Cryobiology, 2001, 42: 274-285.
[31] 钱建新， 顾小强， 焦晓栋， 等. 冷冻消融序贯化疗治疗晚期非小细胞肺癌的疗效观察[J]. 介入放射学杂志， 2014， 23：579-583.
[32] 易峰涛， 宋华志， 陈辉莉， 等. 氩氦刀联合放疗治疗晚期肺癌[J]. 实用癌症杂志， 2004， 19：527-529.
[33] 周红桃， 牛立志， 周?亮， 等. 冷消融联合放射性碘粒子植入治疗不可切除的肺癌[J]. 中国肺癌杂志， 2008， 11：780-783.
[34] 王文辉， 李奋强， 李?立， 等. 多排螺旋CT引导下经皮氩氦刀冷冻消融术结合植入125I粒子治疗肺癌的近期疗效观察[J]. 介入放射学杂志， 2010， 19：554-557.
[35] Lin M, Liang SZ, Wang XH, et al. Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer[J]. Immunol Res, 2017, 65: 880-887.
[36] 李?娜， 薄常文， 邹长鹏， 等. 氩氦刀冷冻联合CIK细胞免疫治疗非小细胞肺癌的临床疗效[J]. 中国现代医学杂志， 2014， 24：36-40.
[37] Biaoxue R, Shuanying Y, Wei L, et al. Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients[J]. Curr Med Res Opin, 2012, 28: 1699-1708.
[38] Gu XY, Jiang Z, Fang W. Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced non-small cell lung cancer[J]. J Int Med Res, 2011, 39: 1736-1743.
[39] Padda S, Kothary N, Donington J, et al. Complications of ablative therapies in lung cancer[J]. Clin Lung Cancer, 2008, 9: 122-126.
相似文献/References:
[1]卢雄,陈芳,林云,等.射频消融联合支气管动脉灌注多西他赛治疗非小细胞肺癌的临床应用[J].介入放射学杂志,2010,(05):410.
LU Xiong,CHEN Fang,LIN Yun,et al.Clinical application of radiofrequency ablation combined with bronchial artery infusion of docetaxel in treating non－small cell lung cancer[J].journal interventional radiology,2010,(04):410.
[2]周毅,蒋忠仆,王海亭,等.PET－CT引导在放射性粒子植入治疗肺癌中的价值[J].介入放射学杂志,2010,(05):389.
ZHOU Yi,JIANG Zhongpu,WANG Haiting,et al.Evaluation of radioactive seeds implantation under PET－CT guidance for the treatment of central lung cancer with obstructive atelectasis[J].journal interventional radiology,2010,(04):389.
[3]王文辉,李奋强,李立,等.多排螺旋CT引导下经皮氩氦刀冷冻消融术结合植入125I粒子治疗肺癌的近期疗效观察[J].介入放射学杂志,2010,(07):554.
WANG Wenhui,LI Fenqiang,LI Li,et al.MSCT－guided percutaneous cryoablation combined with １２５ I－seed implantation for the treatment of lung cancer：an observation of short－term efficacy[J].journal interventional radiology,2010,(04):554.
[4]任丽香,赵卫,沈进,等.肺癌支气管动脉卡铂灌注化疗与栓塞的药代动力学研究[J].介入放射学杂志,2010,(08):657.
REN Lixiang,ZHAO Wei,SHEN Jin,et al.Treatment of lung cancer with bronchial arterial carboplatin infusion and embolization：a pharmaco－kinetic study[J].journal interventional radiology,2010,(04):657.
[5]杜海军,斯艳阳,郭立文.125 I粒子植入联合支气管动脉灌注治疗中晚期肺癌的临床应用[J].介入放射学杂志,2010,(08):661.
DU Haijun,SI Yanyang,GUO Liwen.The clinical application of １２５ I seeds implantation together with bronchial arterial infusion chemotherapy for the treatment of advanced lung cancer[J].journal interventional radiology,2010,(04):661.
[6]高从敬,万向荣,陈才保,等.晚期肺癌支气管动脉和肺动脉的X线解剖及临床意义[J].介入放射学杂志,1997,(03):136.
[7]曾巨浪,李彦豪,夏四元,等.肺癌支气管动脉血供类型及对介入方法和疗效的影响[J].介入放射学杂志,1998,(02):81.
[8]张希全,周宗文,张锐,等.支气管动脉起源异常及肺癌多支供血在灌注治疗中的重要性[J].介入放射学杂志,1994,(01):24.
[9]瞿幼存,李玉梅,刘子江,等.晚期肺癌并胸腔积液的双介入治疗——附40例报道[J].介入放射学杂志,1995,(01):26.
[10]马海明 杜志刚 郑德海 徐全增.肺癌栓塞化疗致脑皮层广泛栓塞一例[J].介入放射学杂志,2006,(04):213.
MA Hai-ming,DU Zhi-gang,ZHENG De-hai,et al.Extensive infarction of cerebral cortex derived from chemo-embolization in lung cancer：case report[J].journal interventional radiology,2006,(04):213.